Opinion

Video

Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy

Panelists discuss how treatment continuation decisions for amyloid-targeting therapies involve comprehensive assessment of multiple factors including cognitive and functional changes measured through standardized tools, occurrence and severity of adverse events, treatment adherence capabilities, impact on patient/caregiver quality of life, disease progression rate, emerging safety signals, and ongoing dialogue about evolving treatment goals and expectations.

Video content above is prompted by the following:

  • How do you decide whether to continue or discontinue treatment with an amyloid-targeting therapy?
Related Videos
1 expert in this video
1 expert in this video
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo